|
![]() |
|||
|
||||
OverviewThis book is a collection of discussions and presentations made by leading experts during a workshop to review the results of recent empirical studies on the effectiveness of chemopreventive agents on the reduction of cancer risk. The topics selected were intended to cover the main areas of research in this field over the last 5-10 years, as well as important issues concerning the design of research studies, cost-effectiveness of chemoprevention, and ethical concerns. A set of conclusions and recommendations are included to provide a guide to formulating future public health policy and research strategy. Full Product DetailsAuthor: M. Hakema , etc. , V. Beral (Doctor, Gibson Building, The Radcliffe Infirmary, Oxford) , E. BuiattiPublisher: International Agency for Research on Cancer Imprint: International Agency for Research on Cancer Volume: No.136 Dimensions: Width: 17.00cm , Height: 0.80cm , Length: 24.00cm Weight: 0.283kg ISBN: 9789283221364ISBN 10: 9283221362 Pages: 140 Publication Date: 25 July 1996 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: In Print ![]() This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsWhy chemoprevention?; Methodological issues in the design of primary prevention trials; Chemoprevention of cancers of the oral cavity and the head and neck; Chemoprevention of oesophageal cancer; Chemoprevention of stomach cancer; Chemoprevention of primary liver cancer; European intervention trials of colorectal cancer prevention; Colon cancer: A USA viewpoint; Why did antioxidants not protect against lung cancer in the Alpha-Tocopherol, Beta-Carotene cancer Prevention study?; Chemoprevention of lung cancer: The b-carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers; Chemoprevention of breast cancer with fenretinide; Chemoprevention of breast cancer with tamoxifen; Chemoprevention of skin cancer; Ethical issues of intervention trials in cancer; Behavioural intervention versus chemoprevention; Cost-effectiveness considerations in chemoprevention of cancer; Conclusions and recommendationsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |